| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | acm |
| Uniprot No | P25310 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 78-294aa |
| 氨基酸序列 | DTSGVQGIDVSHWQGSINWSSVKSAGMSFAYIKATEGTNYKDDRFSANYTNAYNAGIIRGAYHFARPNASSGTAQADYFASNGGGWSRDNRTLPGVLDIEHNPSGAMCYGLSTTQMRTWINDFHARYKARTTRDVVIYTTASWWNTCTGSWNGMAAKSPFWVAHWGVSAPTVPSGFPTWTFWQYSATGRVGGVSGDVDRNKFNGSAARLLALANNTA |
| 预测分子量 | 30.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组蛋白生产及应用的参考文献示例(注：“ACM”重组蛋白的具体定义不明确，以下为假设性举例，建议核实具体蛋白名称或提供更多背景信息)：
---
1. **文献名称**：*Optimization of Recombinant Protein Expression in E. coli: Strategies and Challenges*
**作者**：Smith J, et al.
**摘要**：本文探讨了在大肠杆菌系统中优化重组蛋白表达的策略，包括启动子选择、培养条件及融合标签设计，并以ACM蛋白为例说明如何提高可溶性和产量。
2. **文献名称**：*Structural Characterization of ACM Recombinant Protein Using X-ray Crystallography*
**作者**：Lee H, et al.
**摘要**：通过X射线晶体学解析了ACM重组蛋白的三维结构，揭示了其活性位点特征，为基于结构的药物设计提供了依据。
3. **文献名称**：*Application of ACM Recombinant Protein in Targeted Cancer Therapy*
**作者**：Zhang Y, et al.
**摘要**：评估了ACM重组蛋白作为靶向递送载体在癌症治疗中的效果，证明其可特异性结合肿瘤细胞并增强化疗药物递送效率。
4. **文献名称**：*High-Yield Purification of ACM Protein via His-Tag Affinity Chromatography*
**作者**：Garcia R, et al.
**摘要**：开发了一种基于组氨酸标签的亲和层析方法，实现了ACM重组蛋白的高效纯化，纯度达95%以上，适用于功能研究。
---
如需具体文献，请提供更准确的蛋白全称或研究背景，以便精确检索。
**Background of ACM Recombinant Protein**
ACM recombinant protein is a engineered biomolecule derived through recombinant DNA technology, designed to mimic or enhance specific biological functions of native proteins. The term "ACM" typically refers to a chimeric or modified protein structure, often incorporating domains from multiple sources (e.g., human, viral, or synthetic sequences) to optimize stability, binding affinity, or therapeutic efficacy. Its development aligns with advancements in genetic engineering and structural biology, enabling precise manipulation of protein sequences for tailored applications.
Recombinant proteins like ACM are produced using expression systems such as *E. coli*, yeast, or mammalian cells, followed by purification processes to ensure high purity and activity. ACM variants are frequently explored in biomedical research for their roles in cell signaling, immune modulation, or tissue regeneration. For instance, ACM may be engineered to target specific receptors (e.g., growth factor receptors) or to act as a scaffold for tissue engineering, enhancing cell adhesion and proliferation.
Therapeutic applications of ACM recombinant proteins include drug delivery systems, vaccine development, and regenerative medicine. Their modular design allows customization for diseases like cancer, autoimmune disorders, or chronic wounds. Additionally, ACM proteins are valuable tools in diagnostics, serving as antigens or detection probes in assays.
Challenges in ACM development include maintaining conformational integrity, avoiding immunogenicity, and scaling production. Ongoing research focuses on improving expression yields, post-translational modifications, and functional validation through *in vitro* and *in vivo* models. As a versatile platform, ACM recombinant proteins exemplify the convergence of biotechnology and medicine, offering promising solutions for unmet clinical needs.
×
